Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
Anna Spreafico, Alya Heirali, Daniel Vilarim Araújo, et al.
Annals of Oncology (2023) Vol. 34, Iss. 6, pp. 520-530
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 697-715
Closed Access | Times Cited: 53
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Johannes R. Björk, Laura A. Bolte, Andrew Maltez Thomas, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 785-796
Open Access | Times Cited: 48
Exploiting bacteria for cancer immunotherapy
Seong Young Kwon, Hien Thi-Thu Ngo, Jinbae Son, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 569-589
Closed Access | Times Cited: 45
Role of the microbiota in response to and recovery from cancer therapy
Stephen J. Blake, Yochai Wolf, Ben Boursi, et al.
Nature reviews. Immunology (2023) Vol. 24, Iss. 5, pp. 308-325
Closed Access | Times Cited: 41
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Ze-Hua Li, Weixi Xiong, Liang Zhu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 30
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
Anqi Lin, Aimin Jiang, Lihaoyun Huang, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 3
The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
Liliang Xia, Xiaokuan Zhu, Ying Wang, et al.
Cancer Letters (2024) Vol. 598, pp. 217123-217123
Open Access | Times Cited: 6
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
Sreya Duttagupta, Taiki Hakozaki, Bertrand Routy, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9406-9427
Open Access | Times Cited: 13
Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Jiexi Yan, Lu Yang, Qingmiao Ren, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Precision microbial regulation: Strategies for modulating GIT microbiota for host health
Zhong Pei, Qin Li, Yanmei Zhang, et al.
iMetaOmics. (2025)
Open Access
Assessment of ecological fidelity of human microbiome-associated mice in observational studies and an interventional trial
Matthew K. Wong, Eric Armstrong, Alya Heirali, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Oncobiomics: Leveraging Microbiome Translational Research in Immuno-Oncology for Clinical-Practice Changes
Carolina Alves Costa Silva, Andrew A. Almonte, Laurence Zitvogel
Biomolecules (2025) Vol. 15, Iss. 4, pp. 504-504
Open Access
Gut microbiota and gastrointestinal tumors: insights from a bibliometric analysis
Chaofan Chen, Xiaolan Wang, Xu Han, et al.
Frontiers in Microbiology (2025) Vol. 16
Open Access
Exploring the role of gut microbiome in autoimmune diseases: A comprehensive review
Hongli Wang, Yueshu Cai, W.‐M. Wu, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 12, pp. 103654-103654
Closed Access | Times Cited: 4
Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors
Matthew K. Wong, Giselle M. Boukhaled, Eric Armstrong, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010681-e010681
Open Access
Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification
Mingyao Huang, Quansong Ji, Huiyan Huang, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access
Pangenomic analysis identifies correlations between Akkermansia species and subspecies and human health outcomes
Katherine D. Mueller, María E. Panzetta, Lauren Davey, et al.
Microbiome Research Reports (2024) Vol. 3, Iss. 3
Open Access | Times Cited: 3
Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic
Steph A. Pang, Arielle Elkrief, Mariana Pilon Capella, et al.
Current Oncology (2023) Vol. 30, Iss. 9, pp. 7852-7859
Open Access | Times Cited: 7
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Yao Jiang, Dingjiacheng Jia, Yong Sun, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 12
Open Access | Times Cited: 7
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study
Marc Oliva, Alya Heirali, Geoffrey Alan Watson, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 12, pp. 1936-1942
Closed Access | Times Cited: 2
Microbes as medicine
Brendan A. Daisley, Emma Allen‐Vercoe
Annals of the New York Academy of Sciences (2024) Vol. 1541, Iss. 1, pp. 63-82
Open Access | Times Cited: 2
Narrative Review: Advancing Dysbiosis Treatment in Onco-Hematology with Microbiome-Based Therapeutic Approach
Salomé Biennier, Mathieu Fontaine, Aurore Duquenoy, et al.
Microorganisms (2024) Vol. 12, Iss. 11, pp. 2256-2256
Open Access | Times Cited: 2
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy
Jasmijn I. Verhoef, Ediz Klont, Frans J. van Overveld, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 11, pp. 1179-1191
Open Access | Times Cited: 5
Principles and Terminology for Host–Microbiome–Drug Interactions
Alya Heirali, Shirin Moossavi, Marie‐Claire Arrieta, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 4
Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
Giulia Gabrielli, Roni Shouval, Guido Ghilardi, et al.
HemaSphere (2023) Vol. 7, Iss. 9, pp. e950-e950
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top